Targeted sequencing
Swift Biosciences Presents Accel-Amplicon Plus Oncology Panels
Swift Biosciences today announced the commercial release of Accel-Amplicon Plus™ NGS panels for cancer detection - a set of nine tumor–specific and highly specialized genetic panels designed for targeted cancer sequencing. Accel-Amplicon technology provides the possibility of simultaneous detection of single-nucleotide variations, copying of several variations, as well as minor inclusions and deletions for complex coverage of sites at the exon level in clinically relevant genes. This technique also allows researchers to combine pre-tested content and their own goals in a quick, single-sample analysis, thus creating more informative and flexible working procedures in order to achieve their scientific objectives.
Each tumor carries a unique combination of genomic changes that can determine the growth rate of the tumor and its response to treatment. Targeted sequencing using focused, multigenic analytical panels is an accurate and informative method for the rapid identification of clinically significant variations in known or hypothetical cancer cells. However, the introduction of oncological genetic panels requires experience in the field of bioinformatics, which allows identifying genetic markers and additional resources for creating, optimizing and verifying the analysis.
Accel-Amplicon Plus provides the possibility of modular combination, which gives translational laboratories increased flexibility to implement multiple strategies at once. Laboratories may prefer an extensive set of genes for complex tumor profiling, and subsequently refine the content to the level of the most informative markers, or start with a focused analysis for routine screening of known and clinically significant variations. Each analysis can contain up to 1,500 amplicons in a panel. All of them have been developed and practically tested by Swift specialists, and are also fully compatible with blurred FFPE samples or diluted liquid biopsy samples.
"Accel-Amplicon Plus cancer panels have the potential to revolutionize cancer research," said Haley Fiske, Chief Commercial Officer of Swift Biosciences. "By combining pre–validated and customizable content in a single dashboard, clinical researchers can extract the maximum amount of data from each tumor sample and thereby accelerate the process of detecting and screening cancer variations."
Accel-Amplicon Plus oncological panels include nine analytical kits:
Disease Panels
- Accel-Amplicon Plus™ Colorectal Cancer Panel
- Accel-Amplicon Plus™ Lynch Syndrome Panel
- Accel-Amplicon Plus™ Lung Cancer Panel
- Accel-Amplicon Plus™ Myeloid Panel
Genetic Panels
- 57G Accel-Amplicon Plus™ General Cancer Profiling Panel
- Comprehensive genetic panel TP53 Accel-Amplicon Plus™
- Accel-Amplicon Plus™ BRCA1 and BRCA2 Gene Panel
- Panel of genes BRCA 1, BRCA 2 and PALB 2 Accel-Amplicon Plus™
- Accel-Amplicon Plus™ REFR Panel
The main properties and advantages of Accel-Amplicon Plus oncological NGS panels include:
- The panels cover thousands of clinically significant mutations contained in the COSMIC and ClinVar databases, including those found in mutagenesis hotspots, as well as at exon and full-gen levels in key genes.
- The allelic frequency of >1% of rare variations is detected, allowing the identification of germinal and somatic mutations within the framework of a single analysis.
- They provide stable performance and are able to work with split FFPE samples weighing up to 10 nanograms or limited samples, for example, cell-free DNA, fine needle punctate or other derivatives of small biopsy.
- Compatible with all Illumina sequencers.
Thanks to the extremely informative content, simple protocol and reliable results, the panels are suitable for various application scenarios in oncology, including:
- Detection and confirmation of low-frequency somatic variations
- Profiling of tumors in fresh or preserved samples
- Screening for predisposition to diseases, early detection and control of relapses
- Therapeutic efficacy analysis and monitoring
Simultaneously with the release of the Accel-Amplicon Plus Cancer Panel, the campaign presented Swift Bioinformatics Resources, a number of commercial and publicly available solutions for accelerated analysis of large sets of NGS data. The first two tools support the Swift targeted sequencing procedure – Primerclip™, a publicly available tool for pruning a primer, and FAST Analysis™, software from Genialis for intuitive detection of variations, combining the functions of alignment, identification of alleles and generation of a summary report.
Accel-Amplicon Plus oncological NGS panels are already available for wide sale. For more information, visit the website www.swiftbiosci.com .
Portal "Eternal youth" http://vechnayamolodost.ru